In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
Professor Warren Clements, interventional radiologist and head of the UAE service at The Alfred, said despite the proven safety and efficacy of the procedure – which was developed in the 1990s – it is simply not provided as an option to many women, something he urgently wants to change.
“Fibroids are highly prevalent in society and women need access to a range of different treatments so that they can choose what is the best for them,” Prof Clements said in an interview with Australian Health Journal.
“Every year, many women have a hysterectomy who would be suitable for a non-surgical alternative. UAE is an amazing non-surgical treatment and allows women to keep their uterus if they want to.”
The procedure is all done through a single pinhole incision, whereas a hysterectomy requires open surgery. It involves using low-dose x-rays and contrast dye to guide catheters through the arteries towards fibroids in the uterus. A medication is used to block the blood supply to the fibroids, which causes them to shrink. The procedure takes about half an hour, is done under ‘twilight’ sedation, and only requires one overnight recovery stay.
”Many women aren’t aware that this is a very minor procedure compared to hysterectomy,” Prof Clements said. “Women can resume normal activities the following day. The recovery is short, and most women can go back to work within a week. More than 90 per cent of women with heavy periods will have significant improvement in their symptoms after UAE.”
Professor Warren Clements, is also Honorary Researcher – Interventional Radiology, National Trauma Research Institute, Professor, Interventional Radiologist (IR) and the Head of Fluoroscopy in the Department of Radiology at Alfred Health. He is also a Fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR).
Credit: Alfred Health
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
From paediatric nursing to leadership & private hospital general management
With over 20 years of experience in the Australian and international healthcare sectors, Georgia Banks is a dedicated and results-driven health professional with a proven track record in clinical, financial, human resources, and strategic management. Passionate about delivering high-quality patient care, Georgia possesses an authentic leadership style that fosters engagement, collaboration, and continuous improvement.
Currently serving as General Manager at Hobart Private Hospital within Healthscope, Georgia has been instrumental in driving operational excellence, enhancing patient experience, and supporting staff development. Her leadership has played a key role in aligning hospital services with strategic priorities while fostering a culture of accountability and innovation.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
